Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1426-1434

  Noonan, Kimberly ^a   Rudraraju, Lakshmi ^a   Ferguson, Anna ^a   Emerling, Amy ^a   Pasetti, Marcela F ^b   Huff, Carol A ^a   Borrello, Ivan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; LENALIDOMIDE; PNEUMOCOCCUS VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ANTIBODY TITER; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT DURATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOMODULATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PNEUMOCOCCAL VACCINES; T-LYMPHOCYTES; THALIDOMIDE; VACCINES, CONJUGATE;

EID: 84857770908     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1221     Document Type: Article

References (34)

1. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs 2005;14:1411-8. (Pubitemid 41601455)
2. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
3. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
4. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007;25:4423-30. (Pubitemid 350013848)
5. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-7.
6. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21. (Pubitemid 44061362)
7. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32. (Pubitemid 36618002)
8. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90. (Pubitemid 38268973)
9. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45.
10. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.
11. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, et al. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 2010;51:1015-9.
12. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772-8.
13. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168:4914-9. (Pubitemid 34495953)
14. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-61. (Pubitemid 38495811)
15. Ayello J, Berg SL, Krailo M, Ven CVD, Ingle AM, Lewis D, et al. Lenalidomide (LMID) significantly enhances circulating serum levels of IL-2 and IL-15 levels, NK expansion and activation and NK and LAK cytotoxicity in children with refractory/recurrent solid tumors: A Children's Oncology Group Phase I Consortium Report. In: Proceedings of the 50th Annual Meeting and Exposition of ASH; 2008 Dec 6-9; San Francisco, CA; Washington, DC: ASH; 2008. Abstract nr 107.
16. Hollander N. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma. Crit Rev Immunol 2009;29:399-418.
17. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11:1230-7. (Pubitemid 43093671)
18. Concepcion N, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998;5:199-204. (Pubitemid 28161189)
19. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8:266-72. (Pubitemid 32217054)
20. Staveley-O' Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83. (Pubitemid 28124932)
21. Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227-37.
22. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-20.
23. Dasanu CA. Immune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract 2011 Aug 22. [Epub ahead of print].
24. Nucci M, Anaissie E. Infections in patientswith multiplemyeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211-25.
25. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, et al. Bone marrow as a priming site for T-cell responses to bloodborne antigen. Nat Med 2003;9:1151-7. (Pubitemid 37173699)
26. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17 producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010;116:3380-2.
27. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
28. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
29. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301-4. (Pubitemid 43053555)
30. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11. (Pubitemid 44154611)
31. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
32. Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010;9:4.
33. Di Rosa F. T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow. Immunol Cell Biol 2009;87:20-9.
34. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005;65:2026-34. (Pubitemid 40478633)